Method for discrimination of metaplasias from neoplastic or preneoplastic lesions

Patent metadata

Field	Value
Publication number	US-10246751-B2
Application number	US-201715479961-A
Country	US
Kind code	B2
Filing date	Apr 5, 2017
Priority date	Apr 9, 2002
Publication date	Apr 2, 2019
Grant date	Apr 2, 2019

Abstract

The present invention relates to a method for discrimination of p16 INK4a overexpressing metaplasias from neoplastic or preneoplastic p16 INK4a overexpressing lesions by determination of the level of high risk HPV encoded gene-products such as e.g. HPV E2 and/or HPV E7 molecules in biological samples in the course of cytological testing procedures. The method thus enables for reduction of false positive results in the p16 INK4a based detection of anogenital lesions in cytological testing procedures.

First claim

What is claimed is:

1. A method for screening a uterine cervical cytology sample, comprising:
(a) obtaining at least one slide having the uterine cervical cytology sample deposited thereon;
(b) staining the uterine cytology sample with a labeled oligonucleotide probe that specifically binds p16 INK4a mRNA and is complementary to p16 INK4a mRNA in the sample by in situ hybridization, wherein the label of the oligonucleotide probe that is complementary to the p16 INK4a mRNA generates a first reporter signal;
(c) staining the uterine cervical cytology sample with a labelled oligonucleotide probe that specifically binds a high risk HPV (hr-HPV) gene-product and is complementary to a mRNA of the high risk HPV (hr-HPV) gene-product by in situ hybridization, wherein said high risk HPV gene-product is encoded by a gene selected from the group consisting of HPV E7 gene, HPV E2 gene, HPV E6 gene, HPV L1 gene, and HPV L2 gene, wherein the label of the oligonucleotide probe that is complementary to the mRNA of the hr-HPV gene product generates a second reporter signal; and
(d) detecting in the uterine cytology sample:
(d1) the simultaneous-presence of cells stained with the label generating the first reporter signal and cells stained with the label generating the second reporter signal, or
(d2) the presence of cells stained with the label generating the first reporter signal and the absence of cells stained with the label generating the second reporter signal.

2. The method according to claim 1 , wherein the high risk HPV gene-product is encoded by the HPV E7 gene.

3. The method according to claim 1 , wherein the high risk HPV gene-product is encoded by the HPV E2 or the HPV E6 gene.

4. The method according to claim 1 , wherein the high risk HPV gene-product is encoded by the HPV L1 or the HPV L2 gene.

5. The method of claim 1 , wherein the staining of (b) and the staining of (c) are performed on the same slide, and wherein the first reporter signal and the second reporter signal are different.

6. The method of claim 5 , wherein the agent generating the first reporter signal and the agent generating the second reporter signal are different fluorescent labels.

7. The method of claim 5 , wherein the agent generating the first reporter signal and the agent generating the second reporter signal are different colored compounds.

8. The method of claim 1 , wherein the staining of (b) and the staining of (c) are performed on different slides.

9. The method of claim 8 , wherein the agent generating the first reporter signal and the agent generating the second reporter signal are fluorescent labels or colored compounds.

10. The method according to claim 9 , wherein the colored compound that generates the first reporter signal and the second reporter signal is diaminobenzidine.

11. A method of preparing a uterine cervical cytology sample for microscopic evaluation, said method comprising:
(a) obtaining a slide having the uterine cervical cytology sample deposited thereon;
(b) staining the uterine cervical cytology sample on the slide by in situ hybridization for both:
(b1) p16 INK4a mRNA, wherein the stain for p16 INK4a mRNA is an agent that specifically binds p16 INK4a mRNA and gene rates a first reporter signal; and
(b2) a high risk HPV (hrHPV) mRNA encoded by a gene selected from the group consisting of HPV E7 gene, HPV E2 gene, HPV E6 gene, HPV L1 gene, and HPV L2 gene, wherein the stain for the hrHPV is an agent that specifically binds the high risk HPV mRNA and generates a second reporter signal, wherein the first reporter signal is distinguishable from the second reporter signal.

12. The method of claim 11 , wherein the agent generating the first reporter signal and the agent generating the second reporter signal are different fluorescent labels or different colored compounds.

13. The method according to claim 11 , wherein the high risk HPV gene-product is encoded by the HPV E7 gene.

14. The method according to claim 11 , wherein the high risk HPV gene-product is encoded by the HPV E2 or the HPV E6 gene.

15. The method according to claim 11 , wherein the high risk HPV gene-product is encoded by the HPV L1 or the HPV L2 gene.

16. A method of preparing a uterine cervical cytology sample for microscopic evaluation, said method comprising:
(a) obtaining at least two slides having the uterine cervical cytology sample deposited thereon;
(b) staining the uterine cervical sample on at least one of the slides by in situ hybridization for p16 INK4a mRNA with an agent that specifically binds p16 INK4a mRNA and generates a first reporter signal; and
(c) staining the uterine cervical sample on at least one of the slides by in situ hybridization for a high risk HPV (hrHPV) mRNA with an agent that specifically binds the high risk HPV mRNA and generates a reporter signal, wherein the hrHPV is encoded by a gene selected from the group consisting of HPV E7 gene, HPV E2 gene, HPV E6 gene, HPV L1 gene, and HPV L2 gene, wherein the stain for the hrHPV is an agent that generates a second reporter signal, wherein the first reporter signal is distinguishable from the second reporter signal.

17. The method of claim 16 , wherein the agent generating the first reporter signal and the agent generating the second reporter signal are fluorescent labels or colored compounds.

18. The method according to claim 16 , wherein the high risk HPV gene-product is encoded by the HPV E7 gene.

19. The method according to claim 16 , wherein the high risk HPV gene-product is encoded by the HPV E2 or the HPV E6 gene.

20. The method according to claim 16 , wherein the high risk HPV gene-product is encoded by the HPV L1 or the HPV L2 gene.

Assignees

• Ventana Med Syst Inc

Inventors

• Ridder Ruediger
• Von Knebel Doeberitz Magnus
• Martin Peter

Classifications

• G01N33/5755

  of the uterine cervix, uterine corpus or endometrium · CPC title

• C12Q1/708

  for papilloma · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• G01N33/57411

  Physics · mapped topic

• C12Q2600/158

  Expression markers · CPC title